What is BFRI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BFRI?

P/E (TTM) is n/a and 52-week range is $0.56 to $1.66 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BFRI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BFRI?

The company profile lists revenue (TTM) near $53M, net income (TTM) near -$731M, EPS (TTM) near -$0.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Biofrontera Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Woburn, Massachusetts, US, 14.8M shares outstanding, ISIN US09077D2099 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Biofrontera Inc

$BFRI

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

Employees

Website

www.biofrontera-us.com/

IPO

2021-10-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US09077D2099

Headquarters

Woburn, Massachusetts, US

Shares outstanding

14.8M

NAICS sector

Manufacturing

Institutional ownership

16.00%

Browse other companiesFree AI scores and summaries for more stocks